Jan Styczynski

Summary

Affiliation: Collegium Medicum
Country: Poland

Publications

  1. ncbi Ex vivo modulation of response to prednisolone in childhood acute lymphoblastic leukaemia
    Jan Styczynski
    Department of Paediatric Haematology and Oncology, Collegium Medicum of Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland
    Br J Haematol 133:397-9. 2006
  2. ncbi Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder
    Krzysztof Czyzewski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Leuk Lymphoma 54:503-6. 2013
  3. ncbi Individual tumor response testing in multiple relapsed acute myeloid leukemia in children
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Anticancer Res 33:1189-93. 2013
  4. ncbi Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Anticancer Res 32:5495-9. 2012
  5. ncbi Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Blood 119:2935-42. 2012
  6. ncbi [Cytogenetics and in vitro drug resistance of acute leukemia in children and adults]
    Jan Styczynski
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy, Uniwersytet im Mikołaja Kopernika
    Postepy Hig Med Dosw (Online) 60:527-37. 2006
  7. ncbi Activity of bortezomib in glioblastoma
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Laboratory of Clinical and Experimental Oncology, Nicolaus Copernicus University, Bydgoszcz, Poland
    Anticancer Res 26:4499-503. 2006
  8. ncbi [Efficacy and toxicity of intravenous busulfan-based conditioning treatment before hAematopoietic stem cell transplantation in children: preliminary report]
    Jan Styczynski
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy, Uniwersytet im Mikołaja Kopernika, ul Curie Skłodowskiej 9, 85 094 Bydgoszcz, Poland
    Med Wieku Rozwoj 12:1098-104. 2008
  9. ncbi Drug resistance in childhood acute myeloid leukemia
    J Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Bydgoszcz, Poland
    Curr Pharm Biotechnol 8:59-75. 2007
  10. ncbi Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Medical College, Nicolaus Copernicus University, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Anticancer Res 27:1547-51. 2007

Collaborators

Detail Information

Publications56

  1. ncbi Ex vivo modulation of response to prednisolone in childhood acute lymphoblastic leukaemia
    Jan Styczynski
    Department of Paediatric Haematology and Oncology, Collegium Medicum of Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland
    Br J Haematol 133:397-9. 2006
    ....
  2. ncbi Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder
    Krzysztof Czyzewski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Leuk Lymphoma 54:503-6. 2013
    ..In conclusion, intrathecal rituximab administration seems to be an effective and safe method of treatment of CNS-EBV-PTLD in pediatric stem cell recipients. We recommend this treatment modality for further investigation...
  3. ncbi Individual tumor response testing in multiple relapsed acute myeloid leukemia in children
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Anticancer Res 33:1189-93. 2013
    ..The analysis of the individualized tumor response testing (ITRT) at first and subsequent relapse in children with acute myeloid leukemia (AML)...
  4. ncbi Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Anticancer Res 32:5495-9. 2012
    ....
  5. ncbi Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Blood 119:2935-42. 2012
    ..We conclude that PBSC and BM collection are safe procedures in children...
  6. ncbi [Cytogenetics and in vitro drug resistance of acute leukemia in children and adults]
    Jan Styczynski
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy, Uniwersytet im Mikołaja Kopernika
    Postepy Hig Med Dosw (Online) 60:527-37. 2006
    ..Knowledge on the karyotype-related drug resistance profile might enable the use of targeted therapy in resistant/refractory acute leukemia both in children and adults...
  7. ncbi Activity of bortezomib in glioblastoma
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Laboratory of Clinical and Experimental Oncology, Nicolaus Copernicus University, Bydgoszcz, Poland
    Anticancer Res 26:4499-503. 2006
    ..The aim of the present study was to analyze the activity of bortezomib in glioblastoma cell lines in comparison with that in a pediatric acute lymphoblastic leukemia cell line...
  8. ncbi [Efficacy and toxicity of intravenous busulfan-based conditioning treatment before hAematopoietic stem cell transplantation in children: preliminary report]
    Jan Styczynski
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy, Uniwersytet im Mikołaja Kopernika, ul Curie Skłodowskiej 9, 85 094 Bydgoszcz, Poland
    Med Wieku Rozwoj 12:1098-104. 2008
    ..An intravenous form of busulfan has been developed to replace oral busulfan in conditioning treatment prior to haematopoietic stem cell transplantation (HSCT)...
  9. ncbi Drug resistance in childhood acute myeloid leukemia
    J Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Bydgoszcz, Poland
    Curr Pharm Biotechnol 8:59-75. 2007
    ..Pediatric and adult AML, respectively, are possibly equally drug resistant on initial diagnosis and at relapse. In contrast to ALL, the prognostic value of in vitro drug resistance in childhood AML has not been well documented yet...
  10. ncbi Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Medical College, Nicolaus Copernicus University, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Anticancer Res 27:1547-51. 2007
    ..The aim of the study was the analysis of the impact of the ex vivo drug resistance profile in a cohort of 44 children with AML undergoing hematopoietic stem cell transplantation (HSCT)...
  11. ncbi Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Bydgoszcz, Poland
    Anticancer Res 28:1927-31. 2008
    ..The role of cellular drug resistance in childhood acute myeloid leukemia (AML) has not yet been established. The aim of the study was the analysis of the clinical value of ex vivo drug resistance in pediatric AML...
  12. ncbi Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, ul Curie Sklodowskiej 9, 85 094, Bydgoszcz, Poland
    J Cancer Res Clin Oncol 133:875-93. 2007
    ....
  13. ncbi [Systematic review and meta-analysis of epidemiology, prophylaxis and therapy of infections with viral hepatitis B and C in Polish paediatric oncology centres]
    Jan Styczynski
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy, Uniwersytet im Mikołaja Kopernika, ul Curie Skłodowskiej 9, 85 094 Bydgoszcz, Poland
    Med Wieku Rozwoj 12:1056-61. 2008
    ..Summary of published data on epidemiology, prophylaxis and therapy of HBV and HCV infections in Polish paediatric oncology centres...
  14. ncbi [G-CSF - primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children]
    Jan Styczynski
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy, Uniwersytet im Mikołaja Kopernika, ul Curie Skłodowskiej 9, 85 094 Bydgoszcz, Poland
    Med Wieku Rozwoj 12:1112-6. 2008
    ..Collection of G-CSF-stimulated haematopoietic stem cells from peripheral blood in adults belongs to standard procedures in transplantology. The data on collection of G-CSF-stimulated bone marrow, both in adults and children, are lacking...
  15. ncbi Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Acta Biochim Pol 54:717-26. 2007
    ..The molecules and pathways specific for cancer stem cells, which contribute to their drug resistance, are potential targets for new therapeutic strategies...
  16. ncbi Prevention of infectious complications in pediatric HSCT
    J Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Bone Marrow Transplant 42:S77-81. 2008
    ..No differences in prophylaxis strategy and efficacy among age groups are reported. With changing practices, transplant teams are encouraged to review local patterns of prophylaxis strategy...
  17. ncbi Ex vivo activity of thalidomide in childhood acute leukemia
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Ludwik Rydygier s Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Leuk Lymphoma 47:1123-8. 2006
    ..Thalidomide potentiated ex vivo sensitivity of childhood ALL cells to prednisolone and cytarabine, while no sensitization effect was observed in AML cells...
  18. ncbi Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Anticancer Res 29:1643-50. 2009
    ..Clofarabine is a second-generation nucleoside analogue. The aim of the study was the analysis of ex vivo activity of clofarabine and 14 other anticancer drugs in pediatric and adult acute lymphoblastic (ALL) and myeloid (AML) leukemia...
  19. ncbi [KIR-NKAT2 expression and monocytoid dendritic cells transformation in children diagnosed for immune deficiency: a pilot study]
    Jan Styczynski
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy, Uniwersytet im Mikołaja Kopernika, ul Curie Skłodowskiej 9, 85 094 Bydgoszcz
    Med Wieku Rozwoj 13:66-70. 2009
    ..Its presence might contribute to disabling in elimination of infected cells and causing chronic infection. Another unknown parameter related to functionality of the immune system might be monocyte ability to form dendritic cells...
  20. ncbi In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses
    J Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum Bydgoszcz UMK, Bydgoszcz 85 094, Poland
    Neoplasma 52:74-8. 2005
    ..All tested drugs presented significant cross-resistance in each of analyzed subgroups. In summary, tested nucleoside analogues presented relatively good activity against childhood leukemias at relapse stage...
  21. ncbi Calcified fibromatosis of the neck in 4-year old girl: rapid growth, rapid therapy
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, University of Nicolaus Copernicus, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Int J Pediatr Otorhinolaryngol 69:847-52. 2005
    ..After surgical resection of neck tumor, residual mass persisted both in the neck and in the mediastinum in 6 years of follow-up without signs of progression...
  22. ncbi Alternative medicine remedies might stimulate viability of leukemic cells
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum of Bydgoszcz, Nicolaus Copernicus University of Torun, Bydgoszcz, Poland
    Pediatr Blood Cancer 46:94-8. 2006
    ..Ex vivo activity of three products of alternative therapy against leukemic and normal cells was analyzed...
  23. ncbi Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases
    J Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Transpl Infect Dis 11:383-92. 2009
    ..6% and 41.0%, respectively. Finally, chemotherapy seems not to contribute to improved survival of patients with PTLD after HSCT and antiviral agents are not active against PTLD...
  24. ncbi The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Medical University, Bydgoszcz, Poland
    Acta Biochim Pol 49:99-107. 2002
    ..These results might have a practical impact on the rational design of new chemotherapy protocols...
  25. ncbi Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Medical University Bydgoszcz, Bydgoszcz, Poland
    Leuk Lymphoma 43:1843-8. 2002
    ..In conclusion this study shows that no drug was found which, on average, was more effective in AML than in ALL samples. The sensitivity of myeloblasts to platinum derivatives might have prognostic value...
  26. ncbi Cross-resistance to five glucocorticoids in childhood acute lymphoblastic and non-lymphoblastic leukemia samples tested by the MTT assay: preliminary report
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Medical University, Bydgoszcz, Poland
    Acta Biochim Pol 49:93-8. 2002
    ..038) and HC (54-fold, p = 0.059) when compared with ALL on initial diagnosis. A significant cross-resistance among all the glucocorticoids used was found. Only in some individual cases the cross-resistance was less pronounced...
  27. ncbi Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia
    Joanna Szczepanek
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Anticancer Res 30:2119-24. 2010
    ..Bortezomib was the only compound which was more active in T-ALL than in common/pre-B-ALL paediatric samples. In conclusion, bortezomib had good ex vivo activity in paediatric T-ALL samples...
  28. ncbi Course of viral hepatitis B and combined B and C hepatitis in children treated for neoplastic diseases
    Sylwia Kołtan
    Department and Clinic of Paediatrics, Haematology and Oncology, Medical University, Bydgoszcz, Poland
    Med Sci Monit 8:CR274-9. 2002
    ..Patients with tumors, because of immune deficits, seem to be at risk of rapid liver disease progression. Little is known about the course of HCV and dual HBV-HCV infections in such patients...
  29. ncbi Expression profiles of signal transduction genes in ex vivo drug-resistant pediatric acute lymphoblastic leukemia
    Joanna Szczepanek
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Anticancer Res 32:503-6. 2012
    ..Identification of signal transduction genes related to drug resistance in pediatric acute lymphoblastic leukemia (ALL)...
  30. ncbi Gene expression signatures and ex vivo drug sensitivity profiles in children with acute lymphoblastic leukemia
    Joanna Szczepanek
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    J Appl Genet 53:83-91. 2012
    ..We hypothesize that drug sensitivity in pediatric ALL is driven by specific molecular mechanisms that correlate with gene expression profiles assessed by microarray analysis...
  31. ncbi In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Medical University, Bydgoszcz, Poland
    Acta Biochim Pol 49:221-5. 2002
    ..001) and 5 (p = 0.001), respectively. All oxazaphosphorines presented highly significant cross-resistance. Glufosfamide presented high activity against lymphoblasts both on diagnosis and on relapse...
  32. ncbi Decrease of dual hepatitis B and C virus infections in children with cancer: changes in risk factors over 30 years
    Sylwia Koltan
    Department of Pediatric Hematology and Oncology, Medical University, Bydgoszcz, Poland
    Haematologica 89:251-2. 2004
  33. ncbi Individualized tumor response testing profile has a prognostic value in childhood acute leukemias: multicenter non-interventional long-term follow-up study
    Magdalena Piatkowska
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Leuk Lymphoma 54:1256-62. 2013
    ..For patients with AML, no factor had prognostic value for pDFS in univariate analysis, while ITRT to cytarabine almost reached significance. In conclusion, ITRT can possibly be regarded as a risk factor in childhood acute leukemias...
  34. ncbi Prognostic value of persistent peripheral blood and bone marrow lymphoblasts on day 15 of therapy in childhood acute lymphoblastic leukemia as detected by flow cytometry
    Anna Jaworska-Posadzy
    Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University, Bydgoszcz, Poland
    Anticancer Res 31:1453-7. 2011
    ..Aim: The predictive value of residual disease measured by flow cytometry at day 15 of induction therapy was analyzed in 182 children treated for acute lymphoblastic leukemia (ALL)...
  35. ncbi Relapse of acute lymphoblastic leukemia in children in the context of microarray analyses
    Joanna Szczepanek
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Curie Skłodowskiej 9, 85 094, Bydgoszcz, Poland
    Arch Immunol Ther Exp (Warsz) 59:61-8. 2011
    ..Current status and future perspectives of microarray data on gene expression and drug resistance profile in relapsed pediatric ALL are discussed in this review...
  36. ncbi [Progress in the molecular classification of neoplasms in children]
    Joanna Szczepanek
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy, Uniwersytet im Mikołaja
    Postepy Hig Med Dosw (Online) 62:222-40. 2008
    ..This type of strategy has already been used in several types of pediatric cancer, such as leukemia, lymphoma, and sarcoma. In this review the possibilities of a microarray-based classification of pediatric cancers are presented...
  37. ncbi Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Medical University Bydgoszcz, Bydgoszcz, Poland
    Pediatr Blood Cancer 42:195-9. 2004
    ..These observations suggest that other, than cellular drug resistance, factors play a key role in therapy failure of relapsed childhood AML...
  38. ncbi Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia
    Hanna Janiszewska
    Department of Clinical Genetics, Collegium Medicum, Nicolaus Copernicus University, ul Sklodowskiej Curie 9, Bydgoszcz 85 094, Poland
    Ann Hematol 88:1193-8. 2009
    ..In this study, we have shown that changes in the expression of MDR1 gene after short-term incubation of lymphoblasts with prednisolone may have prognostic value in pediatric de novo ALL patients...
  39. ncbi Is the cancer stem cell population "a player" in multi-drug resistance?
    Tomasz Drewa
    Department of Tissue Engineering, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Acta Pol Pharm 65:493-500. 2008
    ....
  40. ncbi Identification of the genes expression profile associated with the ex vivo resistance to etoposide in childhood acute leukemias
    Joanna Szczepanek
    Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Postepy Hig Med Dosw (Online) 66:401-8. 2012
    ..In this study we analyzed the gene expression profile in correlation with the profile of ex vivo resistance to etoposide in children with acute leukemias...
  41. ncbi [Complementary and alternative medicine treatment in children with cancer. Preliminary report]
    Karolina Duleba
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy, Uniwersytet im Mikołaja Kopernika, ul Curie Skłodowskiej 9, 85 094 Bydgoszcz, Poland
    Med Wieku Rozwoj 12:1155-60. 2008
    ..A growing interest in complementary and alternative medicine (CAM) is observed in treatment of patients with cancer. The use of CAM often leads to delay or resignation from anticancer treatment...
  42. ncbi Cell cycle, melanin contents and apoptosis processes in B16 and Cloudman S91 mouse melanoma cells after exposure to cytostatic drugs
    Dorota M Olszewska-Słonina
    Department of Medical Biology, Collegium Medicum, Nicolaus Copernicus University, Karłowicza 24, PL 85 092 Bydgoszcz, Poland
    Acta Pol Pharm 64:469-78. 2007
    ..Slight increase of melanin content in melanoma cells can be a cell answer to free radicals generation by some cytostatic drugs like adriblastin, actinomycin D and vincristine...
  43. ncbi Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Ludwik Rydygier s Collegium Medicum of Bydgoszcz, Nicolaus Copernicus University of Torun, Poland
    Anticancer Res 25:2253-8. 2005
    ..One of the possibilities to circumvent glucocorticoid resistance is the use of new compounds, such as cortivazol (CVZ), which has two binding sites for the glucocorticoid receptor...
  44. ncbi Can conception of prostate cancer stem cells influence treatment dedicated to patients with disseminated disease?
    Tomasz Drewa
    Department of Tissue Engineering, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
    Med Hypotheses 71:694-9. 2008
    ..Disseminated prostate cancer must be treated with agents directed toward stem cells, while hormone-therapy must be only an additional treatment leading to the decrease of tumor burden...
  45. ncbi [Skin biopsy in diagnosis of chronic graft-versus-host disease in patients after allogeneic haematopoietic stem cell transplantation: pathologist's point of view on quantitative scoring system]
    Dariusz Grzanka
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy, Uniwersytet im Mikołaja Kopernika, ul Curie Skłodowskiej 9, 85 094 Bydgoszcz, Poland
    Med Wieku Rozwoj 12:1105-11. 2008
    ..Recently presented Consensus NIH (National Health Institute, Bethesda, USA) of histopathologic (HP) analysis is still complex and intrinsically divergent, thus clinically difficult to implement...
  46. ncbi Health-related quality of life among paediatric survivors of primary brain tumours and acute leukaemia
    Monika Pogorzala
    Department of Paediatric Haematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, ul Curie Skłodowskiej 9, 85 094 Bydgoszcz, Poland
    Qual Life Res 19:191-8. 2010
    ..Comparative assessment of the HRQL of paediatric survivors of brain tumours (BT) and of acute leukaemia against a population of their healthy peers...
  47. ncbi Differences in significance of drug resistance mechanisms between adult and childhood acute lymphoblastic leukemia
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Medical University, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Haematologia (Budap) 32:313-25. 2002
    ..The underlying mechanisms for these differences are still largely unknown; however, knowledge about drug resistance mechanisms can lead to new therapeutic options...
  48. ncbi In vitro activity of glufosfamide in childhood acute leukemia
    Jan Styczynski
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Bydgoszcz, Poland
    Anticancer Res 22:247-50. 2002
    ..In conclusion, in vitro activity of glufosfamide is comparable to ifosfamide. Glufosfamide shows high activity against lymphoblasts both on diagnosis and on relapse, however it cannot circumvent resistance to other oxazaphosphorines...
  49. ncbi [Imatinib mesylate in treatment of childhood chronic myeloid leukaemia. Preliminary report]
    Monika Pogorzała
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera, Uniwersytet Mikołaja Kopernika, ul Curie Sklodowskiej 9, 85 094 Bydgoszcz, Poland
    Med Wieku Rozwoj 10:603-12. 2006
    ..THE AIM of this preliminary study was to estimate the efficacy and adverse events of imatinib, a selective tyrosine kinase inhibitor, in children with chronic myeloid leukaemia...
  50. ncbi [Gene expression profiles in acute lymphoblastic leukemia in children and adults]
    Joanna Szczepanek
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy, Uniwersytet im Mikołaja Kopernika
    Postepy Hig Med Dosw (Online) 61:519-33. 2007
    ..This review presents the current status of knowledge on gene expression profiles in ALL in children and adults...
  51. ncbi Progenitor cells are responsible for formation primary epithelial cultures in the prostate epithelial model
    Tomasz Drewa
    Department of Tissue Engineering, Chair of Medical Biology, Nicolaus Copernicus University, Karlowicza 24, 85 092, Bydgoszcz, Poland
    Int Urol Nephrol 39:851-7. 2007
    ..The primary epithelial cell culture collapsed in a few days after the CD133-positive ASC were removed. We concluded that the epithelial progenitor cells are responsible for establishing primary prostate epithelial cultures in vitro...
  52. ncbi [Physicians attitudes towards complementary and alternative medicine in patients with cancer: preliminary report from pediatric and oncology centers]
    Karolina Duleba
    Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im Ludwika Rydygiera w Bydgoszczy Uniwersytet im Mikołaja Kopernika, ul Curie Skłodowskiej 9, 85 094 Bydgoszcz, Poland
    Med Wieku Rozwoj 12:1148-54. 2008
    ..Knowledge of oncologists regarding CAM methods is an important factor in professional and safe anti-cancer therapy...
  53. ncbi In vitro drug resistance profiles of adult acute lymphoblastic leukemia: possible explanation for difference in outcome to similar therapeutic regimens
    Jan Styczynski
    Department of Pediatric Hematology and Oncology, Medical University, Bydgoszcz, Poland
    Leuk Lymphoma 43:301-7. 2002
    ..It seems that age itself, more than drug resistance profile, reflects factors which have direct effect on chemotherapy response in adult ALL...
  54. ncbi Unusual profiles of pediatric acute lymphoblastic leukemia with MLL gene rearrangement
    Malgorzata Kubicka
    Leuk Lymphoma 48:2083-6. 2007
  55. ncbi Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia?
    Jan Styczynski
    J Clin Oncol 22:963-4. 2004
  56. ncbi Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia
    Lidia Gil
    Department of Hematology, University of Medical Sciences, Poznan, Poland
    Anticancer Res 27:4021-5. 2007
    ..Bortezomib is an inhibitor of proteasome and NF-kappaB, with activity in various solid tumors and hematological malignancies...